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Carotid atheromatous disease is an important cause of stroke and represents a key target in stroke prevention.
Randomized trials have shown the efﬁcacy of carotid endarterectomy in secondary stroke prevention. Carotid stenting
presents a less invasive alternative to surgical intervention. Advances in medical management, if compliance can be
ensured, are leading to improvement in outcomes when implemented as sole therapy in the treatment of atherosclerotic
carotid stenosis. This includes lifestyle modiﬁcation, blood pressure control, and antiplatelet and statin therapy. Over the
last 20 years, the annual rate of ipsilateral stroke associated with asymptomatic carotid stenosis has decreased from 2% to
4% to less than 1%. This is largely due to improvements in medical therapy. However, despite numerous trials and years of
clinical research, the optimal management of symptomatic and asymptomatic carotid disease remains controversial. This
article presents and summarizes the evidence supporting best medical treatment for carotid artery stenosis. (J Vasc Surg
2013;58:1129-39.)Internal carotid artery stenosis is an important cause of
ischemic stroke, and the treatment of carotid artery stenosis
has been a topic of intense debate over the last 30 years. The
beneﬁts of surgical intervention in severe symptomatic
stenosis have been well documented by the North American
Symptomatic Carotid Endarterectomy Trial (NASCET)
and European Carotid Surgery Trial (ECST) trials.1,2
Major advances have been made regarding medical
therapy alongside lifestyle changes over the last 20 years
since the ﬁrst trials were published, and there is emerging
evidence in favor of aggressive medical management that
may reduce the compelling indications for surgery/stent-
ing in asymptomatic populations.3
This report aims to evaluate the evidence of best
medical treatment for carotid artery stenosis.
METHODS
A literature search of MEDLINE, Cochrane, and
EMBASE databases was performed to identify all studies
that evaluated the use of statins, antiplatelets, anticoa-
gulants, antihypertensives, and antiglycemics in vascular
disease. The studies considered for review were cohortthe Department of Vascular Surgery, Royal Free Hampstead National
ealth Service Trust Hospital.
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RESULTS
Statin therapy. Studies investigating the effect of statin
therapy in patients with carotid artery stenosis and stroke
rates are listed in Table I.4-11 The majority (ﬁve RCTs)
used atorvastatin as one part of the study.4-6,9,10 In only one
of the RCTs, atorvastatinwas shown to have a nonsigniﬁcant
reduction in relative risk (RR) of stroke.6 A systematic
review further showed that atorvastatin consistently reduced
low-density lipoprotein (LDL) levels to <76 mg/dL. Each
10% reduction in LDL reduced the risk of stroke by 15%
(95% conﬁdence interval [CI], 6.7-23.6).8 Three studies
looked at simvastatin, showing that there was a signiﬁcant
regression in carotid plaques, and there was also a signiﬁcant
reduction in incidence of stroke.7,10,11 The Study of Coro-
nary Atheroma by Intravascular Ultrasound: Effect of
Rosuvastatin vs Atorvastatin (SATURN) randomly assigned
1385 patients to full-dose statin treatment. The study
showed that both statins signiﬁcantly reduced LDL
cholesterol levels.4 There was a regression in atherosclerosis
(68.5% vs 63.2% with atorvastatin), but there was no
statistical difference between them (P ¼ .17). Over the
course of 104 weeks, there were two nonfatal strokes with
atorvastain and three with rosuvastatin.4
Antiplatelet therapy. Antiplatelet therapy has been
shown to reduce the incidence of stroke by 25% (P <
.0001).12 One meta-analysis analyzed 21 trials involving
18,270 patients.12 It showed that most of the evidence
supported the use of aspirin in the range of 75 mg to
150 mg and was unable to support the use of dual1129
Table I. Trials investigating the effect of statins on the incidence of stroke
Author Study design Inclusion criteria Aim
Nicholls SJ et al;
SATURN
Study, 20114
RCT, double blind,
multicenter
At least 1 vessel with 20% stenosis in
coronary arteries on angiography.
LDL >100 mg/dL if no prior statin
treatment.
LDL >80 mg/dL if prior treatment.
To assess the effects of two intensive statin
regimens on coronary atherosclerosis
progression using intravascular USS
using PAV
Amarenco et al;
SPARCL
Study, 20065
RCT, double blind,
multicenter
1) No CAD
2) TIA or stroke within last
6 months
Time from randomization to ﬁrst nonfatal
or fatal stroke
Sillesen H et al;
Secondary
analysis of
SPARCL
Study, 20086
As per SPARCL study
Analysis of patients
included those with
carotid artery stenosis
Patients with carotid artery stenosis Greatest reduction of stroke in patients with
carotid artery stenosis
Hegland O
et al, 20017
Single-center prospective
cohort, longitudinal
study
1) Carotid artery stenosis >40%
2) >2 measurements of stenosis
3) No previous surgical intervention
To assess the effect of simvastatin on carotid
plaques
Paraskevas KI
et al, 20078
Systematic review of
statin effect on carotid
IMT and carotid artery
disease progression
rates
All studies assessing impact of statin
therapy on carotid IMT progression
and stroke rates
To deﬁne the role of statin treatment in
patients with carotid artery disease
LaRosa J et al;
TNT Study,
20059
RCT, double blind,
multicenter
CHD and LDL level <130 mg/dL 1) Reducing LDL cholesterol
<100 mg/dL in stable CHD
2) The occurrence of death, MI,
fatal or nonfatal stroke
Pedersen et al;
IDEAL
Study,
200510
RCT, open label,
multicenter
1) <80 years
2) History of acute MI
Occurrence of a major coronary event
(eg, death, nonfatal MI)
Heart
Protection
Study,
200211
RCT, double blind,
multicenter
1) LDL > 135 mg/dL,
2) History of
a) CHD,
b) occlusive disease of
noncoronary arteries
(ie TIA, stroke,
c) Previous CEA
To assess the long-term effects of lowering
LDL cholesterol on vascular and
nonvascular mortality
CAD, Coronary artery disease; CEA, carotid endarterectomy; CHD, coronary heart disease, CI, conﬁdence interval; IMT, intima-media thickness; LDL, low-
density lipoprotein; MI, myocardial infarction; NA, not available; PAV, percent atheroma volume; RCT, randomized controlled trial; RR, relative risk; TIA,
transient ischemic attack; USS, ultrasound scan.
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trial compared aspirin and clopidogrel against aspirin alone
in both symptomatic and asymptomatic patients. Initial
analysis showed that the rate of primary event of stroke wassimilar in both groups (6.8% vs 7.3%; P ¼ .22).13 A
Cochrane review assessed the efﬁcacy and safety of dipyr-
idamole in the secondary prevention of vascular events
(death from all vascular causes, nonfatal stroke/myocardial
Treatment Patients Results/main conclusions
Atorvastatin 80 mg vs
rosuvastatin 40 mg
1385 (691/694) Patients with rosuvastatin had lower levels of LDL than those treated
with atorvastatin (62.6 vs 70.2 mg/dL; P < .001).
Two-thirds of patients demonstrated some form of regression of
atherosclerosis (68.5% vs 63.3% with atorvastatin).
Though overall PAV decreased by 1.22% (95% CI, 1.52-0.90;
P ¼ .17) with rosuvastatin and 0.99% (95% CI, 1.19-0.63)
with atorvastatin.
Nonfatal stroke 3 (0.4%) for rosuvastatin and 2 (0.3%) for atorvastatin
Difﬁcult to apply to asymptomatic patients.
Atorvastatin 80 mg daily
vs placebo
4731 (2365/2366) Atorvastatin: 16% RR reduction (95% CI, 0.71-0.99; P ¼ .03) and
35% reduction in major coronary vascular events.
Atorvastatin 80 mg vs
placebo
1007
51% stenosis (629%)
In atorvastatin treatment group
1) 33% reduction in the risk of any stroke (HR, 0.67; 95% CI,
0.47-0.94; P ¼ .02)
2) 43% reduction in risk of major coronary event (HR, 0.57; 95%
CI, 0.32-1.00; P ¼ .05)
Absolute risk reduction of stroke was 1% per year (numbers needed
to treat, 20 over 5 years).
Simvastatin treated vs no
statin at baseline
observation
230 (147/171); 318 arteries 13.5% regression in carotid stenosis in the simvastatin group and
a mean progression of carotid stenosis of 6.4% in the untreated
group.
NA Carotid IMT
1) 2 meta-analysis
(n > 93,443)
2) 24 studies (n ¼ 6727)
Statin and stroke rates
27 studies (n ¼ 127,833)
Carotid IMT and statin
Total weighted mean difference of carotid IMT progression between
statins vs placebo was 22.35% (95% CI, 18.14-26.56%; P <
.00001)
Atorvastatin 80 mg/d for 12 months resulted in a 48.5% decrease in
LDL cholesterol (148 6 32 to 76 6 23 mg/dL). Pravastatin
reduced LDL levels by 27.2% (155 6 34 to 110 6 30 mg/dL).
Statins and stroke rates
Each 10% reduction in LDL cholesterol was estimated to reduce the
risk of stroke by 15.6% (95% CI, 6.7-23.6).
Clinical vascular events
Statin therapy was associated with a 12% reduction in all-cause
mortality per mmol/L reduction in LDL cholesterol (95% CI,
9%-16%; P < .0001).
Atorvastatin low dose
(10 mg) vs high dose
(80 mg)
10,001 (5006/4995) Fatal or nonfatal stroke; 10 mg, 155 (3.1%) vs 80 mg, 117 (2.3%)
(HR, 0.75; 95% CI, 0.59-0.96; P ¼ .02).
Cerebrovascular events (stroke or TIA) 10 mg, 250 (5.0%) vs 80 mg,
196 (3.9%) (HR, 0.77; 95% CI, 0.64-0.93; P .007).
Mean LDL 77 mg/dL for high-dose and 101 mg/dL for low-dose
treatment.
8.1 vs 5.8%; P < .001 had an adverse event related to treatment for
high dose and low dose respectively.
Atorvastatin 80 mg vs
simvastatin 20 mg
8888 (4449/4439) Secondary outcome: fatal or nonfatal stroke. 151 (3.4%) atorvastatin
vs 174 (3.9%) simvastatin (HR, 0.87; 95% CI, 0.70-1.08; P ¼ .20).
Cardiovascular mortality 223 (5.0%) atorvastatin vs 218 (4.9%)
simvastatin (HR, 1.03; 95% CI, 0.85-1.24; P ¼ .78).
Simvastatin 40 mg vs
placebo
20, 536 (10,269/10,267) 17% reduction in the death rate from vascular causes: 781 (7.6%) for
simvastatin vs 937 (9.1%) for placebo; P < .0001.
25% reduction in incidence of stroke
444 (4.3%) simvastatin vs 585 (5.7%) placebo; P < .0001.
30% reduction in ischemic stroke
290 simvastatin (2.8%) vs 409 placebo (4.0%); P < .0001.
Table I. Continued.
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review looked at 26 RCTs, which compared 39 treatments
in a total of 19,842 patients with the dose varying between
150 mg and 800 mg daily.14 Eighteen trials compareddipyridamole with placebo and showed that it had no
effect on vascular death but did reduce the risk of having
a vascular event RR, 1.02; 95% CI, 0.90-1.17 vs RR,
0.90; 95% CI, 0.83-0.98).14 Combining dipyridamole with
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reduce the risk of having a vascular event similar to that
seen with dipyridamole alone (RR, 1.03; 95% CI,
0.87-1.22 vs RR, 0.90; 95% CI, 0.80-1.00).14 The review
did not ﬁnd any evidence to support the use of dipyr-
idamole as the ﬁrst-line antiplatelet in patients at high risk
of a vascular event.14 Other studies analyzed are presented
in Table II.15-21
Anticoagulant therapy. Anticoagulants have often
been used as an alternative to antiplatelets in patients
with ischemic strokes. A Cochrane review looked at 24
RCTs involving 23,748 patients. The patients enrolled
were either within 24 or 48 hours or within 14 days of
stroke. The studies analyzed unfractionated heparin,
low-molecular-weight heparins, and oral vitamin-K antag-
onists (two trials). The studies showed that routine anti-
coagulation did lead to fewer ischemic strokes but also led
to a signiﬁcantly increased risk of intracranial and extra-
cranial hemorrhage.22 This was supported by another
Cochrane review that showed, in 16,558 patients, that
anticoagulants offered no greater beneﬁt than aspirin but
did have a signiﬁcantly increased risk of causing intracranial
hemorrhage (odds ratio [OR], 2.35, 95% CI, 1.49-3.46).23
In 2007, the Birmingham Atrial Fibrillation (AF) Treat-
ment of the Aged (BAFTA), a randomized study involving
973 patients (warfarin [n ¼ 488] vs aspirin [n ¼ 485])
showed that, after a mean follow-up of 2.7 years, the
incidence of major stroke, intracranial hemorrhage, or
systemic emboli was actually lower in patients taking
warfarin (4.9% [24/288]) vs 9.9% [48/485]).24 The
Prevention in Reversible Ischaemia Trial (SPIRIT)
compared warfarin (international normalized ratio, 3.0-
4.5) against 30 mg aspirin in patients with transient
ischemic attack (TIA) or minor stroke. The trial showed
that there was an increased incidence of stroke, MI, and
major bleeding in patients who took warfarin compared
with aspirin (81/651 vs 36/665 [hazard ratio (HR) 2.3;
95% CI, 1.6-3.5]). Twelve patients in both groups suffered
from stroke, but it was the incidence of major bleeding in
20 patients in the warfarin group compared with two in the
aspirin group that caused the trial to be terminated at the
ﬁrst interim analysis (14-month follow-up).25 A meta-
analysis comparing anticoagulants with control (placebo,
antiplatelet therapy) in 16 studies showed that anticoagu-
lant therapy did not offer any advantage over placebo or
antiplatelet therapy.26
Newer drugs have come on to the market recently,
such as dabigatran (direct thrombin inhibitor), and been
promoted as being superior to warfarin in patients who
have suffered a stroke as a result of cardiac embolism (ie,
AF). The Randomized Evaluation of Long Term Anticoag-
ulant Therapy (RE-LY) Trial assigned 18,113 patients with
AF to either dabigatran at 110 mg or 150 mg twice a
day or warfarin. Stroke or TIA occurred slightly more
frequently in patients taking warfarin than those given
dabigatran at 110-mg and 150-mg doses (2.74% per year
vs 2.32% and 2.07% per year, respectively). Importantly,
with either dose of dabigatran, there was less risk of majorbleeding (3.36% in warfarin, 2.71% and 3.11% with
110-mg or 150-mg dabigatran, respectively).27 The data
for patients with carotid artery stenosis is lacking, and
therefore, it is difﬁcult to promote its use in patients who
have had a stroke as a result of carotid artery stenosis.
Cilostazol. Cilostazol, a phosphodiesterase III inhib-
itor, has shown to be an antiplatelet, vasodilatory, and
antithrombotic agent. One case series looked at 207
patients who had been given cilostazol after carotid artery
stenting. Cilostazol seemed to reduce the incidence of
restenosis, target vessel revascularization, hemorrhage,
death, or thromboembolism (15.0% vs 19.9%; log-rank,
P ¼ .17).28 Another study assessed the impact of cil-
ostazol on carotid artery plaques after carotid endarectomy.
Thirty-four patients were given cilostazol while the
remaining 48 patients were given aspirin (n ¼ 33), ticlo-
pidine (n ¼ 8), clopidogrel (n ¼ 2), or warfarin (n ¼ 5).
Patients were assessed by measuring intimal thickness using
ultrasound for up to 6 years. There was no evidence of
ipslateral or contralateral plaque development in any of the
patients taking cilostazol. In the second group, seven
patients were found to have evidence of restenosis in the
ipslateral or plaque formation in the contralateral artery.
Interestingly, six out of the seven of these patients had
hyperlipidemia. This shows that there is a promising role in
carotid artery stenosis, but higher-powered randomized
trials need to be conducted to establish its true effect.29
Antihypertensive therapy. Control of blood pressure
can lead to a 30% to 40% reduction in stroke and is one of
the most modiﬁable risk factors for carotid artery disease.30
Although target blood pressures are unclear, it is widely
accepted that we should aim for BP <140/90 mm Hg in
nondiabetic patients and <130 mm Hg for patients with
diabetes.30 To date, there have been no studies conducted
to identify the most suitable antihypertensive agent to use
in patients with carotid artery stenosis. A Cochrane review
in 2009 looked at the ﬁrst-line antihypertensive drug
classes and assessed their impact on total mortality (death
from all causes), stroke (fatal and nonfatal), coronary artery
disease (CAD; fatal and nonfatal), and overall reduction in
blood pressure during 1 year. It looked at 24 RCTs
(58,040 patients) and concluded that low-dose thiazides
(bendroﬂuazide <5 mg) were the most effective in
reducing all-cause mortality and morbidity. Angiotensin-
converting enzyme inhibitors were seen to be equally
effective; however, the evidence was less robust.31
The HOPE (Heart Outcomes Prevention Evaluation)
study assessed the role of ramipril in patients with evidence
of vascular disease or diabetes. A total of 9297 patients
were deemed eligible, and 4645 were randomly assigned
to receive 10-mg ramipril. Mean blood pressures were
similar in both treatment and placebo groups, but ramipril
was shown to signiﬁcantly reduce the risk of stroke, with
3.4% of patients having an event compared with 4.9%
in the control group (RR, 0.68; 95% CI, 0.56-0.84;
P < .001).32
A meta-analysis of 13 RCTs involving 105,951 patients
compared beta-blockers with other antihypertensives or
JOURNAL OF VASCULAR SURGERY
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increased in patients taking beta-blockers by as much as
16% (95% CI, 4%-30%; P¼ .009). RR for all-cause mortality
was also increased by 3%. In two studies where blood pres-
sure reduction was most substantial, most of the patients
within the treatment group were also taking additional anti-
hypertensives (mostly thiazides). Beta-blockers were
deemed suboptimal in the treatment of hypertension and
were associated with a higher incidence of stroke than other
antihypertensive agents.33 The meta-analysis failed to
include some important studies such as the Captopril
Prevention Project (CAPPP) and the Veterans Administra-
tion Cooperation Study Group Trial. The CAPPP study
looked at 10,985 patients and randomly assigned them to
captopril, beta-blockers, or diuretics. The RR of stroke
was higher in the captopril arm (189 vs 148; RR, 1.25;
95% CI, 1.01-1.55; P ¼ .04). However, this study was
excluded from the meta-analysis, as it was not possible to
ascertain how many patients received beta-blockers.34 The
Veterans Administration Cooperation Study Group Trial
showed that, even though thiazides (hydrochlorothiazide)
were shown to better at controlling BP than beta-blockers
(propranolol), the incidence of stroke was actually lower in
patients taking beta-blockers.35 This trial was excluded
due to there being a larger reduction (9 mm Hg) in systolic
blood pressure in the thiazide arm. A recent study looked at
44,708 patients with previous MI, history of CAD but no
MI history, and patients with risk factors for CAD. The
study showed that event rates were not signiﬁcantly different
in patients with beta-blocker use compared with those
without beta-blocker use.36
Glycemic control. TheUK prospective Diabetic Study
had 1148 patients and showed that, despite strict BP andgly-
cemic control, there was a nonsigniﬁcant reduction in stroke
rates (21% reduction; P ¼ .13).37 The Action to Control
Cardiovascular risk in Diabetes Study group (ACCORD)
trial randomized 10,251 patients with a mean glycated
hemoglobin level of 8.1% to receive intensive therapy (n ¼
5128) or standard therapy (n ¼ 5123).38 After 1 year, gly-
cated hemoglobin levels of 6.4% were achieved in the
intensive therapy group; however, there was no signiﬁcant
difference in the rate of nonfatal stroke (1.3% vs 1.2%; HR,
1.06; 95% CI, 0.75-1.50; P¼ .74).38 The ADVANCE trial,
a multicenter international trial, enrolled 11,140 patients
and randomized them to either receive perindopril or inda-
pamide for 6 weeks as part of the run-in period.39 Following
this, they were randomly assigned to either continue this
treatment or matching placebo and or receive intensive
glycemic control in the form of gliclazide MR.39 The
regimen resulted in glycated hemoglobin to <6.5% but had
no signiﬁcant impact on stroke incidence (3.8% vs 3.8%).39
Modiﬁable risk factors. Smoking is a known modiﬁ-
able risk factor for carotid artery stenosis. A meta-analysis in
1989 looked at 32 studies to ascertain the relationship
between smoking and stroke. It concluded that smoking
increased the overall RR by 1.5% (95% CI, 1.4-1.6).40 The
Framingham study also showed that men who stopped
smoking were 50% less likely to suffer disease.41 ACochrane review analyzed the effect of various forms of
nicotine replacement therapy in aiding smoking cessation.
The results were variable but did show that nicotine
replacement therapy increased the chance of smoking
cessation by 50% to 75%.42
Physical inactivity and diet are all important risk factors
for the development of vascular disease. A recent prospec-
tive cohort study showed that one serving per day of
red meat was associated with an elevated stroke risk
whereas poultry intake had a 27% (95% CI, 12%-39%)
lower risk.43 The Northern Manhattan Study (population-
based cohort study) looked at the effect of adhering to a
Mediterranean-style diet (MeDi) and the incidence of
ischemic stroke, MI, and vascular death.44 The study, con-
ducted over 9 years, failed to show that adherence to
a Mediterranean-style diet would reduce the incidence of
stroke but did show that it was inversely associated with
the risk of composite outcome of ischemic stroke, MI,
and vascular death (P ¼ .04).4
Patient compliance. Patient adherence to long-term
therapy in most developed countries averages 50%, with
even lower rates in developing countries. A cross-sectional
survey analyzed 635 patients who were taking antihyper-
tensives for hypertension. A total of 370 patients were
found to be noncompliant, and even though the level of
noncompliance did increase with age, the difference was
found to be not statistically signiﬁcant. Forgetfulness was
the main reason cited for noncompliance, followed by
being away from home and drug shortage.45 Other studies
conducted have shown that noncompliance is complex,
and that there is no single solution for improving compli-
ance. Some studies have stated that a patient’s lack of
understanding of drug regimen, side effects, and medica-
tion mistrust all contribute to noncompliance. In clinical
trials where patients are selected into the study and have
greater access to clinicians, compliance rates range between
43% and 78%. Patients with chronic conditions (greater
than 6 months) have been shown to have poorer compli-
ance than those with acute conditions.46DISCUSSION
Carotid endarterectomy (CEA) has proven to be an
effective treatment in preventing ischemic stroke; however,
the majority of studies for this were conducted before the
routine use of statins and the newer antiplatelet drugs.
The medical treatment of carotid artery stenosis has
evolved greatly since the major trials of the 1980s, when,
at that time, aspirin was the mainstay drug treatment.
Now, combination therapy, with antiplatelet, antihyperten-
sive, antidiabetic agents, and treatment of hypercholester-
olemia, together with smoking cessation is the current
best medical management for carotid artery stenosis.
Evidence provided does not support the use of dual anti-
platelet therapy, and there is not enough evidence to
support the use of statin therapy with another lipid-
lowering agent. The Improve-IT trial, which is currently
being conducted, will provide evidence for whether
Table II. Trials investigating antiplatelet treatment in vascular disease
Author Study design Inclusion criteria Aim
Diener HC et al; MATCH
Study, 200415
RCT, double-blind,
multicenter (507 centers
in 28 countries)
TIA or ischemic stroke in last
3 months and had 1 or
more risk factors within the
last 3 years:
a) Previous stroke/MI
b) Diabetes
c) Symptomatic peripheral
vascular disease
Primary end point was:
Ischemic stroke
Vascular death
Rehospitalization for an acute ischemic event
Safety
a) Incidence of life-threatening bleeding
b) Intracranial bleeding
c) Need of >4 units of RBCs
Antithrombotic Trialists
Collaboration, BMJ 200212
Meta-analysis, 287 studies
(up to Sept 1997)
NA To update previous meta-analyses to include
studies up to September 1997.
Main outcome measure:
Serious vascular events
Nonfatal MI
Nonfatal stroke
Vascular death
CAPRIE, 199616 RCT, blinded, international,
multicenter (384)
a) Ischemic stroke >1
week and <6 months
prior to randomization
b) MI onset <35 days
prior to randomization
c) Intermittent
claudication
Patients with CEA
excluded
To assess the impact of clopidogrel on
the reduction of ischemic stroke, MI,
or vascular death in patients with
recent events
European Stroke Prevention
Study 217; Diener HC et al,
1996
RCT, double-blind TIA or stroke within the last
3 months
Primary outcomes
1) Stroke (ﬁrst occurrence fatal and
nonfatal)
2) Death from all causes
Secondary outcomes
1) TIA
2) MI
CHARISMA; Bhatt et al,
200613
RCT, multicenter (768
centers), double-blind,
international
>45 years with one of the
following
a) Multiple atherothrom-
botic risk factors (eg,
DM, asymptomatic
carotid stenosis $70%)
b) CAD
c) Cerebrovascular disease
Primary outcomes
First occurrence of
a) MI
b) Fatal or nonfatal stroke (ischemic and
hemorrhagic)
c) Other cardiovascular disease
ESPRIT,
200618
RCT, multicenter (79),
international
TIA or minor ischemic stroke
(grade #3 modiﬁed Rankin
score) in last 6 months
Patients excluded if there was
a possible cardiac source of
embolism (eg, AF, valvular
heart disease, recent MI)
Primary outcomes
a) Death from all vascular causes
b) Nonfatal stroke
c) Nonfatal MI
d) Major bleeding
CURE; Mehta SR et al, 200019 RCT, international,
multicenter (482 centers)
ACS without ST segment
elevation >1 mm and
within 24 hours of ischemic
symptoms
ECG changes compatible with
ischemia or troponin I >
than twice the upper limit of
normal
Primary outcome
a) Cardiovascular death
b) MI
c) Stroke
ACS, Acute coronary syndrome; AF, atrial ﬁbrillation; BID, twice daily; CAD, coronary artery disease; CEA, carotid endarterectomy; CI, conﬁdence interval;
DM, diabetes mellitus; ECG, electrocardiograph; HR, hazard ratio; MI, myocardial infarction; NA, not applicable; RBCs, red blood cells; RCT, randomized
controlled trial; RR, relative risk; TIA, transient ischemic attack.
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Treatment Patients Results/main conclusion
Aspirin 75 mg vs placebo
All patients also taking
clopidogrel
7599 (3802 placebo þ
clopidogrel 3797 aspirin þ
clopidogrel)
18-month follow-up
Primary outcome was 16% in aspirin group vs 17% in placebo group (P ¼ .244).
Ischemic stroke (fatal or not) 8% in both groups.
3% of patients in the aspirin group had life-threatening bleeding compared with 1% in
the placebo group (RR, 1.26; 95% CI, 0.64-1.88; P < .0001).
GI bleeding was that most common cause (1.4% vs 0.6%). No hemorrhagic
transformation of ischemic stroke.
Beneﬁt-to-risk ratio showed no added beneﬁt of aspirin and clopidogrel.
Antiplatelet vs control
Antiplatelet vs antiplatelet
135,000 (antiplatelet vs
control)
77,000 (antiplatelet vs
antiplatelet)
Antiplatelet therapy produced a 25% reduction in nonfatal strokes (P < .0001)
18, 270 patients/21 trials
29 months of antiplatelet e25 (5%) fewer/1000; P < .0001
Asymptomatic carotid disease 36/339 (10.6%) antiplatelet v 43/337 (12.8%) adjusted
control ¼ 19% (22% reduction, NS)
No evidence to support 500-1000 mg of aspirin (more gastro toxic)
Evidence supports aspirin in the range of 75 mg to 150 mg.
150-300 mg should be given as a loading dose in an acute stroke.
Clopidogrel may be slightly more effective, consider as alternative if aspirin contra-
indicated.
Dual therapy e more research is needed.
Clopidogrel 75 mg vs aspirin
325 mg
19,185 (9553 clopidogrel/
9546 aspirin)
Patients on clopidogrel had annual risk of ischemic stroke/MI/vascular death of
5.32% compared with 5.83% with aspirin.
There was an RR reduction of 8.7% (95% CI, 0.3-16.5; P ¼ .043).
Expect 24 clincial events to be prevented per 1000 patients with clopidogrel compared
with 19 with aspirin.
Four treatment groups
a) Aspirin 25 mg BID
b) 200 mg BID dipyridamole
modiﬁed release
c) Combination of treatment
(a and b)
d) Matched placebo
6602 in total
a) 1649
b) 1654
c) 1650
d) 1649
12.9% stroke rate in aspirin alone, 13.2% in dipyridamole modiﬁed release, 9.9% in
combination, 15.8% in placebo.
No difference between the groups for end point of death (P ¼ .616).
RR reduction for stroke with
1) Aspirin ¼ 18.1% (P ¼ .013)
2) Dipyridamole modiﬁed release ¼ 16.3% (P ¼ .039)
3) Combination treatment ¼ 37.0% (P < .001)
Numbers needed to treat per thousand patients with each treatment group was
1) Aspirin ¼ 29 patients
2) Dipyridamole modiﬁed release ¼ 26 patients
3) Combination of the above two groups ¼ 58 patients
Bleeding was more common when aspirin was administered. Bleeding from
any site
a) Aspirin ¼ 135 patients (8.2%)
b) Dipyridamole modiﬁed release ¼ 77 patients (4.7%)
c) Combination treatment ¼ 144 patients (8.7%)
d) Matched placebo ¼ 74 patients (4.5%)
All patients given aspirin 75
mg-162 mg daily and either
a) Clopidogrel or
b) Matched placebo
15,603
a) Clopidogrel 7802
b) Matched placebo
7801
The rate of primary event was 6.8% with clopidogrel vs 7.3% with the placebo group
(RR, 0.93; 95% CI, 0.83-1.05; P ¼ .22).
The rates of ischemic stroke (nonfatal) were 132 (1.7%) with clopidogrel vs 163
(2.1%) with aspirin alone (RR, 0.81; 95% CI, 0.64-0.98).
All patients given aspirin 30-
325 mg daily and either
a) Dipyridamole modiﬁed
release 200 mg BID
or
b) Matched placebo
2763
a) 1363 aspirin and
dipyridamole modiﬁed
release
b) 1376 aspirin and
placebo
The mean aspirin dose during the study was 7 vs 5 mg daily.
173 patients (13%) with combined therapy and 216 patients (16%) with monotherapy
had at least one primary outcome (HR, 0.80; 95% CI, 0.66-0.98).
The absolute risk reduction with dual therapy is 1.0% per year (95% CI, 0.1-1.8).
The numbers needed to treat with dual therapy to prevent 1 death from all vascular
causes/MI/stroke/bleeding is 104 patients per year (95% CI, 55-106)
Intention to treat for ﬁrst ischemic stroke 96 patients (7%) with dual therapy vs 116
patients (8.4%) with monotherapy (HR. 0.84; 95% CI, 0.64-1.10).
All patients received aspirin and
either
a) Clopidogrel 75 mg or
b) Matched placebo
Loading dose of 300 mg
clopidogrel or matched
placebo given following
allocation
12,563
a) 6259 clopidogrel
b) 6303 placebo
Dual therapy with clopidogrel reduced the risk of primary end points by 20%
(P ¼ .00005).
Death from any cardiovascular cause, nonfatal MI, or stroke was 9.3% (582 patients
with dual therapy (aspirin and clopidogrel) vs 11.4% (719 patients) with
monotherapy (aspirin and placebo) (RR, 0.80; 95% CI, 0.72-0.90; P < .001).
The incidence of stroke was 1.2% (n ¼ 75) with dual therapy and 1.4% (n ¼ 87) with
monotherapy (RR, 0.86; 95% CI, 0.63-1.18).
Major bleeding occurred in 3.7% with dual therapy vs 2.7% with monotherapy
(RR, 1.38; 95% CI, 1.13-1.67; P ¼ .001).
Table II. Continued.
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Author Study design Inclusion criteria Aim
PROFESS Study; RL Sacco et al,
200820
RCT, double-blind, multicenter
(695), international
>50 years of age and ischemic
stroke within the last 90 to
120 days
First reoccurrence of stroke
(ischemic and hemorrhagic)
UK TIA Aspirin Trial; Farrell
et al, 199121
RCT, multicenter (33), blind >40 years TIA or minor
ischemic stroke <3 months
First occurrence of major
stroke/MI
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stroke rates. Results are expected in 2015.
Prompt instigation of effective treatment has been
widely acknowledged as being beneﬁcial, but until
recently, the evidence for this has been lacking. This has
recently been provided by the EXPRESS study (Effect
of urgent treatment of TIA and minor stroke on early
recurrent stroke).47 This single-center, prospective,
population-based study compared two different modali-
ties of management of patients with TIA or stroke, with
the primary outcome being risk of stroke within
90 days. In the initial phase, the general practitioner
(GP) was asked to instigate treatment, whereas those in
phase two had assessment and treatment instigated imme-
diately by the outpatient clinic (comprising a team of
nurses and medical physicians). The risk of stroke was
signiﬁcantly lower in patients during phase two (2%)
than phase one (10%; P ¼ .0001) and showed that timely
initiation of treatment reduced the risk of further early
strokes by 80%.47
Best medical management is now a necessary strategy
in the treatment of asymptomatic and symptomatic carotid
artery stenosis, following surgical intervention such as CEA
or carotid artery stenting when indicated.
The 10-year follow-up for asymptomatic patients who
underwent CEA has recently been completed.
The initial asymptomatic Carotid Surgery Trial 1
(ACST 1), completed in 2004, randomized 3120 patients
with greater than 60% stenosis without neurological symp-
toms to immediate CEA or indeﬁnite deferral of any CEA.
Both groups were given antiplatelet and antihypertensive
therapy, and increasingly over the years, lipid-lowering
therapy. Immediate risk of stroke (<30 days) after CEA
was 3.1%. The annual risk of stroke in patients managed
with medical therapy alone was approximately 2%. Over
5 years of follow-up, the risk of stroke was 3.8% (immediate
CEA) vs 11% for the deferred group (gain, 7.2%; 95% CI,
5.0-9.4; P < .0001). Most of the gain seen was in carotid
territory ischemic strokes (2.7% vs 9.5%). The greatest
reduction was seen in patients with 70% to 90% stenosis.48
The 10-year stroke risk in patients who underwent
CEA was 10.8% compared with 16.9% in those treated
with medical therapy (gain, 6.1%; 95% CI, 2.7-9.4). Thissuggests that, despite being on medical therapy, it is difﬁ-
cult to eliminate the risk of disabling stroke, and that if
CEA is done safely, it should be discussed with all suitable
patients.49
In 2008, the New England Journal of Medicine asked
its readers to state how they would manage a patient with
70% to 80% asymptomatic carotid stenosis. Forty-nine
percent said they would manage the patient medically,
with the remainder opting for CEA (32%) and carotid
artery stenting (19%). This was despite the publication
of two large RCTs showing that CEA conferred a 50%
RR reduction over 5 years (12% to 6%).50 A systematic
review in 2009 analyzed 11 international studies (10
within the hospital setting and one in the primary sector)
involving 3724 patients with 50% to 75% asymptomatic
carotid stenosis.51 They were allocated to either medical
intervention alone or CEA for ipsilateral asymptomatic
or contralateral symptomatic carotid stenosis. There were
statistically signiﬁcant falls in the reported rates of ipsilat-
eral stroke in the medically treated groups (1.4%,
1985-2007) and any-territory stroke (2.3%, 1986-2007;
P < .0012). They were able to demonstrate that, from
mid-1980 to 2001, there was a signiﬁcant reduction in
annual rates of ipsilateral and any-territory stroke with
medical intervention alone, and in 2001, the annual rates
were actually lower than those patients who had under-
went CEA.51 These falls correlated with a 14% fall in
active smokers and also a reduction in baseline mean
blood pressure and total cholesterol.51 A prospective
population-based cohort study of ipsilateral stroke in
patients with $50% asymptomatic carotid artery stenosis
was performed in Oxford between 2002 and 2009.52
The patients were identiﬁed after they were sent for inves-
tigations for TIA or minor ischemic stroke in another
territory.52 Out of 1153 patients, 101 had $50% asymp-
tomatic carotid stenosis, of which 75% had presented
with contralateral carotid territory TIA or stroke. During
a mean follow-up of 3 years (range, 1-84 months), there
were only six ischemic events (two TIA, 50%-69%; three
TIA, 70%-99%).52 Even with the low sample size, they
were able to show that, if patients were prescribed best
medical therapy, then the rates of annual stroke were
lower than in patients undergoing CEA.52 Another
Treatment Patients Results/main conclusion
Aspirin 25 mg daily and
dipyridamole modiﬁed release
200 mg BID vs clopidogrel
and placebo
20,332 (10,181 aspirin
and dipyridamole
modiﬁed release
10,151 clopidogrel)
Premature discontinuation of study with aspirin and dipyridamole modiﬁed release
(29.1% [aspirin and dipyridamole modiﬁed release] vs 22.6% [clopidogrel and
placebo]; P < .001).
Stroke occurred in 1814 patients in total, of which, 916 (9.0%) patients were
taking dual therapy, and 898 (8.8%) were on clopidogrel only (HR, 1.01; 95%
CI, 0.92-1.11).
More hemorrhagic events were noted among aspirin and dipyridamole modiﬁed
release 4.1% vs 3.6% with clopidogrel (HR, 1.15; 95% CI, 1.00-1.32).
Aspirin 600 mg BID or aspirin
300 mg daily or placebo
2435 (815 high-dose
aspirin, 806 low-dose
aspirin, 814 placebo)
No difference in efﬁcacy between the aspirin doses.
Odds of suffering MI/major stroke or vascular death were 15% less in the groups
taking aspirin compared to the placebo group.
Table II. Continued.
JOURNAL OF VASCULAR SURGERY
Volume 58, Number 4 Constantinou et al 1137prospective study assessed 468 patients. One hundred
ninety-nine patients were recruited between 2001 and
2002, and 269 were recruited between 2003 and 2007.
The study showed that, with better control of plasma
lipids and greater prescription of statins, there was a decline
in microemboli (before 2003, 12.6% vs since 2003, 3.7%)
and also a slower rate of carotid plaque progression.53
They were able to show that, in those patients without
evidence of microemboli disease (90% of patients), the
risk of stroke within 1 year was 1% (95% CI, 1.01%-
1.36%).53 If these patients had been offered a surgical
intervention, then their 30-day risk of stroke would have
been 4% to 7% with CEA or 5% to 12% with stenting.54
It has recently been suggested that the presence of carotid
stenosis was associated with cortical and subcortical
atrophy.55 The Second Manifestations of ARTerial
disease-Magnetic Resonance (SMART-MR) study assessed
all patients who presented with some form of arterial
disease (CAD, abdominal aortic aneurysm, cerebrovascular
disease, or peripheral vascular disease). Patients underwent
magnetic resonance imaging at day 1 and during a follow-
up assessment (mean follow-up, 3.9 years; range, 3.0-
5.8 years).55 They were able to demonstrate that in those
patients with >70% stenosis (coefﬁcient of linear
regression, 0.70; 95% CI, 1.08-0.32; P < .005) and
those with bilateral carotid artery disease (coefﬁcient of
linear regression, 0.92; 95% CI, 1.52-0.32; P <
.005), there was a signiﬁcant decrease in total brain and
cortical gray matter volume and a subsequent increase in
ventricular volume.55 These ﬁndings were independent
of cardiovascular risk factors and could be explained by
the stenosis causing cerebral hypoxia in individuals with
poor collateral circulation. The cortical gray matter has
higher oxygen and glucose requirements than white
matter, hence the decline seen in patients with severe
(>70%) or bilateral carotid stenosis.55 This is unfortu-
nately just one piece of the puzzle, and further studies
are required to fully appreciate the relationship between
carotid artery disease, cerebral hypoperfusion, and collat-
eral circulation.
These studies all strengthen the argument that opti-
mizing medical management is now an essential and neces-
sary strategy in all patients with carotid artery stenosis.CONCLUSIONS
There is now convincing evidence to suggest that
advances in medical treatment for carotid artery stenosis
can translate in reduced rates of cerebrovascular events.
All patients with carotid stenosis can beneﬁt from modern
medical treatment with lipid-lowering therapy, antiplatelet
treatment, antihypertensives, and good diabetic control,
together with lifestyle modiﬁcations.
Regardless of the degree of stenosis or whether the
lesion is symptomatic, these simple medical therapies
should be considered ﬁrst-line treatment in all patients
with carotid artery stenosis. A new trial comparing CEA
plus best medical management vs best medical manage-
ment alone would answer the question as to which treat-
ment is really superior.
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